Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients.

Nóra CsikányÁdám KissMáté DériFerenc FeketeAnnamária MinusKatalin TóthManna TemesváriEnikő SárváryLászló BihariZsuzsa GerleiLászló KóboriKatalin Monostory

Published in: British journal of clinical pharmacology (2020)

CYP3A-status guided therapy significantly improved the risk of misdosing induced early adverse effects (acute rejection, nephrotoxicity).

Keyphrases

drug induced
liver failure
high glucose
diabetic rats
respiratory failure
oxidative stress
cell therapy
replacement therapy
mechanical ventilation
extracorporeal membrane oxygenation